Related Experiment Video

Updated: Jun 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Treatment of triple negative breast cancer (TNBC): current options and future perspectives

M De Laurentiis1, D Cianniello, R Caputo

  • 1Department of Breast Oncology, National Cancer Intitute Fondazione Pascale, via Mariano Semmola, Naples, Italy. delauren@unina.it

Cancer Treatment Reviews
|December 7, 2010
PubMed

Insights

Triple-negative breast cancer (TNBC) is a challenging subtype with poor outcomes. This review summarizes current treatments and emerging therapies for TNBC, a type of basal-like breast cancer (BLBC).

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Breast cancer is now recognized as heterogeneous, with distinct subtypes identified through gene expression analysis.
  • These subtypes include hormone receptor (HR)-positive luminal A and B, human epidermal growth receptor 2 (HER2)-positive, and basal-like breast cancer (BLBC).
  • Basal-like breast cancer (BLBC) exhibits the poorest clinical outcomes.

Purpose of the Study:

  • To review the current understanding of triple-negative breast cancer (TNBC).
  • To emphasize the existing treatment strategies for TNBC.
  • To highlight novel therapeutic options currently under development for TNBC.

Main Methods:

  • Utilizes immunohistochemical (IHC) classification for identifying breast cancer subtypes in routine clinical practice.
  • Defines TNBC based on the absence of estrogen receptor, progesterone receptor, and HER2 expression via IHC.
  • Reviews updated knowledge on TNBC, focusing on treatment and therapeutic advancements.

Main Results:

  • Triple-negative breast cancer (TNBC) is closely associated with basal-like breast cancer (BLBC).
  • TNBC presents a significant therapeutic challenge due to the lack of common molecular targets.
  • Current knowledge on TNBC treatment and developing options is summarized.

Conclusions:

  • TNBC, a subtype of BLBC, poses a major challenge in breast cancer treatment.
  • The review provides an update on the management and future therapeutic directions for TNBC.
  • Further research into targeted therapies is crucial for improving outcomes in TNBC patients.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...